Navigation Links
Mindray Announces First Quarter 2009 Financial Results
Date:5/11/2009

SHENZHEN, China, May 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the first quarter ended March 31, 2009.

    Highlights for First Quarter 2009
    -- First quarter 2009 net revenues were $134.2 million, an increase of
       53.5% over the first quarter of 2008
    -- Non-GAAP operating income in the first quarter 2009 was $34.7 million,
       a 12.6% increase from the first quarter of 2008. First quarter 2009
       GAAP operating income was $29.4 million
    -- Accutorr V -- first jointly developed product by Mahwah and Shenzhen
       teams was successfully released to the market.

"Despite weaker-than-expected market trends in US and Europe, we are pleased to report a relatively strong quarter," commented Mr. Xu Hang, Mindray's chairman and co-chief executive officer. "During the quarter, Mindray responded quickly to the challenging market dynamics and initiated measures to effectively control product costs and reduce operating expenses to sustain operating profit growth. We are confident that Mindray will continue to outperform the market in the remainder of 2009 and beyond, as a result of the strength of our highly competitive operating structure which enables us to deliver products that meet the quality, performance and price requirements of our growing global customer base."


                               SUMMARY - 1st Quarter 2009


(in $ millions, except per-share 1Q/2009 1Q/2008 % change

data)

    Net Revenues                           134.2       87.4            53.5%
           Revenues generated in China      62.4       42.8            45.8%
      Revenues generated outside China      71.8       44.6            60.8%
    Non-GAAP Gross Profit (1)               76.3       50.2            52.0%
    GAAP Gross Profit                       74.7       49.4            51.2%
    Non-GAAP Operating Income (1)           34.7       30.8            12.6%
    GAAP Operating Income                   29.4       27.9             5.4%
    Non-GAAP Net Income (1)                 30.5       27.8             9.6%
    GAAP Net Income                         25.3       25.1             1.2%
    Non-GAAP Diluted EPS (1)                0.27       0.25            10.5%
    GAAP Diluted EPS                        0.23       0.22             1.9%

(1) Mindray provides gross margin, R&D expenses, selling expenses, general

        and administrative expenses, operating margin, net income and earnings
        per share on a non-GAAP basis that excludes non-cash, share-based
        compensation expense, acquired intangible assets amortization expense
        and termination payments to enable investors to better assess the
        company's operating performance. The non-GAAP measures are described
        below and reconciled to the corresponding GAAP measure in the section
        below titled "Use of Non-GAAP Financial Measures."

Revenues

Mindray reported net revenues of $134.2 million for the first quarter 2009, a 53.5% increase from $87.4 million for the first quarter 2008.

Net revenues generated in China in the first quarter 2009 increased 45.8% to $62.4 million from $42.8 million for the first quarter 2008, while net revenues generated in international markets in the first quarter 2009 increased 60.8% to $71.8 million from $44.6 million for the first quarter 2008.

Performance by Segment

Patient Monitoring & Life Support Products: Patient monitoring & life support products segment revenues increased 97.4% to $58.6 million from $29.7 million for the first quarter 2008. The patient monitoring & life support products segment contributed 43.7% to the total net revenues in the first quarter 2009.

In-Vitro Diagnostic Products: In-vitro diagnostic products segment revenues increased 8.7% to $32.2 million from $29.7 million in the first quarter 2008. The in-vitro diagnostic products segment contributed 24.0% to the total net revenues in the first quarter 2009.

Medical Imaging Systems: Medical imaging systems segment revenues increased 32.9% to $35.7 million from $26.9 million in the first quarter 2008. The medical imaging systems segment contributed 26.6% to the total net revenues in the first quarter 2009.

Others: Other revenues, which are primarily comprised of extended warranty services revenues, increased 525.1% to $7.6 million from $1.2 million in the first quarter 2008. Other revenues contributed 5.7% to the total net revenues in the first quarter 2009.

The segment revenue amounts discussed above include shipping and handling fees charged to customers.

Gross Margins

First quarter 2009 non-GAAP gross profit was $76.3 million, a 52.0% increase from $50.2 million in the first quarter 2008. First quarter 2009 GAAP gross profit was $74.7 million. Non-GAAP gross margin was 56.9% in the first quarter 2009 compared to 57.4% in the first quarter 2008 and 55.3% in the fourth quarter 2008. First quarter 2009 GAAP gross margin was 55.7%.

Operating Expenses

Non-GAAP selling expenses for the first quarter 2009 were $20.1 million, or 15.0% of the total net revenues, compared to 11.1% in the first quarter 2008 and 15.5% in the fourth quarter 2008. GAAP selling expenses for the first quarter 2009 were $21.8 million.

Non-GAAP general and administrative expenses for the first quarter 2009 were $7.7 million, or 5.7% of the total net revenues, compared to 2.3% in the first quarter 2008 and 8.5% in the fourth quarter 2008. GAAP general and administrative expenses for the first quarter 2009 were $8.8 million.

Non-GAAP research and development expenses for the first quarter 2009 were $13.9 million, or 10.4% of the total net revenues compared to 8.8% in the first quarter 2008 and 9.6% in the fourth quarter 2008. GAAP research and development expenses for the fourth quarter 2008 were $14.7 million.

Total share-based compensation expenses, which were allocated to cost of goods sold and related operating expenses, were $3.0 million in the first quarter 2009 compared to $2.2 million in the first quarter 2008 and $1.6 million in the fourth quarter 2008.

Non-GAAP operating income, as defined below, in the first quarter 2009 was $34.7 million, a 12.6% increase from $30.8 million in the first quarter 2008. Non-GAAP operating margins were 25.9% in the first quarter 2009 compared to 35.2% in the first quarter 2008 and 21.6% in the fourth quarter 2008. GAAP operating income was $29.4 million in the first quarter 2009. GAAP operating margin was 21.9% in the first quarter 2009.

Net Income

First quarter 2009 non-GAAP net income increased 9.6% year-over-year to $30.5 million from $27.8 million in the first quarter 2008. First quarter 2009 GAAP net income was $25.3 million. Non-GAAP net margin was 22.7% in the first quarter 2009 compared to 31.8% in the first quarter 2008 and 21.4% in the fourth quarter 2008. GAAP net margin was 18.9% in the first quarter 2009. First quarter 2009 income tax expense was $4.2 million representing an effective tax rate of 14.3%.

First quarter 2009 basic and diluted non-GAAP earnings per share were $0.28 and $0.27 respectively, compared to $0.26 and $0.25 in first quarter 2008. First quarter 2009 GAAP basic and diluted earnings per share for the quarter were $0.23 and $0.23, respectively, compared to $0.23 and $0.22 in first quarter 2008. Shares used in the computation of diluted earnings per share in the first quarter 2009 were 112.1 million.

Other Select Data

Average accounts receivable days outstanding were 60 days, or $87.7 million, for the first quarter 2009 compared to 40 days, or $89.7 million, for the full year 2008. Inventory turnover was 89 days, or $57.9 million, for the first quarter 2009 compared to 60 days, or $57.5 million, for the full year 2008.

Average accounts payable days outstanding was 58 days, or $39.7 million, for the first quarter 2009 compared to 46 days or $36.5 million, for the full year 2008.

As of March 31, 2009, the company had $261.2 million in cash and cash equivalents and restricted cash. Net cash generated from operating activities and capital expenditures for the first quarter 2009 were $30.7 million and $13.6 million, respectively.

As of March 31, 2009 the company had approximately 5,620 employees compared to 4,050 employees on March 31, 2008 and 5,580 employees on December 31, 2008.

Business Outlook for Full Year 2009

With the continuing uncertainties in many parts of the market Mindray competes in, the company now expects:

    -- 2009 net revenue to grow at a rate of at least 10% year-over-year,
       provided that foreign exchange rates remain constant at RMB6.85 to the
       dollar and $1.33 to the euro.
    -- Non-GAAP EPS to grow 10% over 2008.
    -- Capital expenditure in the range of $40 million to $60 million.
    -- Share based compensation to be $12 million, based on issuances to date,
       which does not take into account of any additional share based
       compensation costs that may come later this year, if any.
    -- Amortization of intangible assets to be $10 million including April
       2006 acquisition of minority interest and May 2008 acquisition of
       Datascope patient monitoring business.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

"The revised guidance reflects more cautious assumptions of the overall market conditions for the remainder of 2009, as the world industry dynamics continued to worsen since earlier this year," commented Mr. Li Xiting, Mindray's president and co-chief executive officer. "For the current year, the China market still represents the strongest growth outlook. The picture outside China is mixed though, with healthy growth from Latin America and Africa coupled with additional growth as a result of our acquisition of our Mahwah operations, partially offset by declines in other sales geographies outside of China. We remain firm in our belief that Mindray's unique vertically integrated business model and strong financial position will allow us to more effectively adapt to fast changing market environments such as the one we are in today. We will continue to build on our cost advantages coupled with effective R&D and solid sales infrastructure to capture substantial growth opportunities in the markets we compete in."

In addition, as announced on March 4, 2009, Mr. Ronald Ede began in his new role of Chief Financial Officer of the company effective on May 8, 2009, replacing Ms. Joyce Hsu. Mr. Ede and Ms. Hsu both remain directors serving on Mindray's board.

Conference Call Information

Mindray's management will hold an earnings conference call at 8:00 AM on May 12, 2009 U.S. Eastern Time (8:00 PM on May 12, 2009 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    Hong Kong:                 +852-3002-1672
    U.S. Toll Free:            +1-800-798-2864
    International:             +1-617-614-6206
    Pass code for all regions: Mindray

A replay of the conference call may be accessed by phone at the following numbers until May 23, 2009.

    U.S. Toll Free: +1-888-286-8010
    International:  +1-617-801-6888
    Pass code:      9482 5654

Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://www.mindray.com .

Use of Non-GAAP Financial Measures

The company has reported for the first quarter 2009 and provided estimates for full year 2009 net income and earning per share on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

    -- Non-GAAP gross profit represents gross profit reported in accordance
       with GAAP, adjusted for the effects of share-based compensation and
       amortization of acquired intangible assets.
    -- Non-GAAP operating income represents operating income reported in
       accordance with GAAP, adjusted for the effects of share-based
       compensation and amortization of acquired intangible assets including,
       but not limited to, termination payments.
    -- Non-GAAP net income represents net income reported in accordance with
       GAAP, adjusted for the effects of share-based compensation and
       amortization of acquired intangible assets including, but not limited
       to, termination payments, all net of related tax impact.
    -- Non-GAAP earnings per share represents non-GAAP net income divided by
       the number of shares used in computing basic and diluted earnings per
       share in accordance with GAAP, and excludes the impact of the deemed
       dividends for the basic calculation.

In addition to Mindray's consolidated financial results under GAAP, the Company also provides non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating profit, non-GAAP selling expenses, non-GAAP general and administrative expenses, non-GAAP R&D expenses, non-GAAP net income and non-GAAP earnings per share on a basic and fully diluted basis. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Mindray's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing Mindray's underlying business performance and operating trends and the Company expects to report operating profit and net income on a non-GAAP basis using a consistent method on a quarterly basis going forward.

The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three months period ended March 31, 2008 and 2009, respectively, in the attached financial information.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements," including those related to the company's market performance, the business outlook for the fiscal year 2009 with respect to net revenues, Non-GAAP EPS, capital expenditure, share based compensation and amortization of intangible assets, the company's ability to grow in various geographic markets, to adapt to changing market environments, to take advantage of cost advantages, and to capture growth opportunities. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Readers are cautioned that these forward- looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, filed on May 8, 2009. Our results of operations for the first quarter of 2009 and for fiscal year 2009 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release. All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://www.mindray.com .



                                    Exhibit 1
                       MINDRAY MEDICAL INTERNATIONAL LIMITED
                       CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (Dollars in thousands)

                                                     As of            As of
                                                 December 31,       March 31,
                                                      2008            2009
                                                       US$             US$
                                                    (audited)     (unaudited)
    ASSETS

    Current assets:
      Cash and cash equivalents                       96,370         103,107
      Restricted cash (note 1)                       119,711         158,059
      Short-term investments                          36,780              --
      Accounts receivable, net                        89,735          87,729
      Inventories                                     57,466          57,879
      Value added tax receivables                     13,566          10,178
      Other receivables                                7,471          10,017
      Prepayments and deposits                         4,503           5,765
      Deferred tax assets                              1,812           1,749
      Total current assets                           427,414         434,483

      Other assets                                     1,724           1,669
      Advances for purchase of plant and
      equipment                                       46,275          35,878
      Property, plant and equipment, net             126,399         131,850
      Land use rights, net                             2,721          15,108
      Deferred tax assets, net                            --           1,243
      Intangible assets, net                          67,004          66,200
      Goodwill                                       114,234         114,206
      Total assets                                   785,771         800,637

    LIABILITIES AND SHAREHOLDERS'
    EQUITY
    Current liabilities:
      Short-term bank loans                          157,007         146,400
      Notes payable                                    7,449           4,606
      Accounts payable                                29,009          35,098
      Advances from customers                          7,523           8,097
      Salaries payables                               16,797          10,076
      Other payables                                  46,911          64,822
      Income taxes payable                            10,727          12,116
      Other taxes payable                              4,398           3,902
      Total current liabilities                      279,821         285,117

    Other long-term payables                           7,120           7,302
    Minority interests                                     2               2
    Deferred tax liabilities, net                        736           1,782

    Shareholders' equity:
      Ordinary shares                                     14              14
      Additional paid-in capital                     274,993         279,453
      Retained earnings                              183,886         187,626
      Accumulated other comprehensive loss            39,199          39,341
      Total shareholders' equity                     498,092         506,434

    Total liabilities and shareholders'
     equity                                          785,771         800,637

    (1) Restricted as the security package required for the bank loans as of
        March 31, 2009. Use of such funds are permitted provided that the
        proportionate amount of debt must be retired concurrently. As of March
        31, 2009, the short-term bank loans can be fully repaid from such
        short-term restricted cash.



                                         Exhibit 2
                          MINDRAY MEDICAL INTERNATIONAL LIMITED
                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
              (Dollars in thousands, except for share and per share data)

                                                Three months ended March 31,
                                                           2008         2009
                                                            US$          US$
                                                     (unaudited)  (unaudited)

      Net revenues
      -PRC                                               42,791       62,370
      - International                                    44,637       71,795

      Net revenues                                       87,428      134,165
      Cost of revenues (note 2)                         (38,002)     (59,424)
      Gross profit                                       49,426       74,741

      Selling expenses (note 2)                         (10,484)     (21,789)
      General and administrative expenses
      (note 2)                                           (2,620)      (8,797)
      Research and development expenses
      (note 2)                                           (8,422)     (14,745)

      Operating income                                   27,900       29,410

      Other income (loss), net                              502         (432)

      Interest income                                     2,358        1,620

      Interest expense                                       (5)      (1,025)
      Income before income taxes and
       minority interests                                30,755       29,573

      Provision for income taxes                         (5,703)      (4,232)

      Minority interests                                     --           --

      Net Income                                         25,052       25,341

      Basic earnings per share                             0.23         0.23

      Diluted earnings per share                           0.22         0.23

      Shares used in the computation of:

      Basic earnings per share                      106,962,659  107,872,202

      Diluted earnings per share                    112,998,260  112,118,964

       (2) Share-based compensation charges incurred during the period related
           to:

      Cost of revenues                                      110          131

      Selling expenses                                      805        1,051

      General and administrative expenses                   571          953

      Research and development expenses                     748          846




                                      Exhibit 3
                         MINDRAY MEDICAL INTERNATIONAL LIMITED
            RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES
                      TO THE NEAREST COMPARABLE GAAP MEASURES
            (Dollars in thousands, except for share and per share data)

                                                 Three months ended March 31,
                                                            2008        2009
                                                      (unaudited) (unaudited)




      Net revenues                                        87,428     134,165

      Non-GAAP net income                                 27,825      30,510
      Non-GAAP net margin                                   31.8%       22.7%
      Amortization of acquired intangible
       assets                                               (657)     (2,208)
      Deferred tax impact related to
       acquired intangible
       assets                                                118         104

      Termination payments                                    --         (84)

      Share-based compensation                            (2,234)     (2,981)

      GAAP net income                                     25,052      25,341
      GAAP net margin                                       28.7%       18.9%

      Non-GAAP income per share - basic                     0.26        0.28

      Non-GAAP income per share - diluted                   0.25        0.27

      GAAP income per share - basic                         0.23        0.23

      GAAP income per share - diluted                       0.22        0.23

       Shares used in computation of:

       Basic earnings per share                      106,962,659 107,872,202

       Diluted earnings per share                    112,998,260 112,118,964

      Non-GAAP operating income                           30,791      34,683
      Non-GAAP operating margin                             35.2%       25.9%
      Amortization of acquired intangible
      assets                                                (657)     (2,208)

      Termination payments                                    --         (84)

      Share-based compensation                            (2,234)     (2,981)

      GAAP operating income                               27,900      29,410
      GAAP operating margin                                 31.9%       21.9%


      Non-GAAP gross profit                               50,193      76,277
      Non-GAAP gross margin                                 57.4%       56.9%
      Amortization of acquired intangible
       assets                                               (657)     (1,405)

      Share-based compensation                              (110)       (131)

      GAAP gross profit                                   49,426      74,741
      GAAP gross margin                                     56.5%       55.7%



    For investor and media inquiries please contact:

    In the U.S:
    FD
     Evan Smith, CFA
     Tel:   +1-212-850-5606
     Email: evan.smith@fd.com

     John Capodanno
     Tel:   +1-212-850-5705
     Email: john.capodanno@fd.com

    In China:
    Mindray
     May Li
     Head Investor Relations
     Tel:   +86-755-2658-2518
     Email: may.li@mindray.com

'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray to Report First Quarter 2009 Financial Results on May 11, 2009
3. Mindray Medical to Exhibit New Products at 61st China International Medical Equipment Fair
4. Mindray Announces Option Exchange Offer
5. Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009
6. Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009
7. Mindray Announces Preliminary 2008 Operating Results
8. Mindray Medical to Present at the 27th Annual J.P. Morgan Healthcare Conference
9. Mindray Medical to Exhibit at RSNA 2008 in Chicago, from November 30th to December 4th, 2008
10. Mindray Announces 2008 Third Quarter and Nine Months Results
11. Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin ... new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved ... who play in the wet and early morning dew or right after a rain shower, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, serving ... a new charity campaign. As part of their ongoing community involvement program, funds ... belief that children deserve a voice, and in the spirit of neighbors helping ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: